AGM.L

Applied Graphene Materials Plc
Applied Graphene - Strategic Review
23rd November 2022, 07:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 2774H
Applied Graphene Materials PLC
23 November 2022
 

This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR").

23 November 2022

Applied Graphene Materials plc

("Applied Graphene Materials", "the Group" or "the Company")

Strategic Review

 

The Company's board of directors has previously outlined its plans to raise further equity in order to fund the Company's operations and the continued development of the business. As announced on 08 November 2022, the Board recently investigated the feasibility of an equity raise with institutional and other investors and concluded that it would not be possible to complete an equity raise successfully at the current time.

 

As announced on 8 November, whilst the Board is pleased with the start that the Company has made to the current financial year, the Company requires additional funding in the near-term in order to continue in operation beyond 31 January 2023.

 

Given the Company's funding position and having regard to the unfavourable conditions in small-cap equity markets, the Board has decided to initiate a strategic review, pursuant to which the Board will consider the options available to maximise value for the Company's shareholders and other stakeholders. Such options could include, but not be limited to, raising additional funding from a specialist debt provider or strategic investor or by realising value from an accelerated sale of the Group's trade and assets or of the shares in the Group's main operating subsidiary. In parallel with the options described above, to seek to protect the financial position of the Company in the event the strategic review does not achieve a satisfactory conclusion, the Board has regrettably decided to commence statutory redundancy consultations with the Company's employees.

 

The Board has appointed Alvarez & Marsal Europe LLP as its financial adviser to manage the strategic review process. Any interested party should contact Alvarez & Marsal at the contact details set out below.

 

The Board will provide further updates to shareholders as appropriate.

 

 

For further information, please contact:

Applied Graphene Materials  +44 (0) 1642 438 214

Adrian Potts, Chief Executive Officer

David Blain, Chief Financial Officer

Alvarez & Marsal Europe LLP +44 (0) 784 107 2042

Alex Baird  abaird@alvarezandmarsal.com

Singer Capital Markets  (Nominated Adviser and Joint Broker) +44 (0) 207 496 3000

Peter Steel / Amanda Gray

Allenby Capital Limited (Joint Broker) +44 (0) 203 328 5656

Nick Athanas / George Payne (Corporate Finance)

Matt Butlin / Kelly Gardiner (Sales and Corporate Broking)

Hudson Sandler  (Financial PR) +44 (0) 207 796 4133

Nick Lyon / Emily Dillon

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBKBBPCBDDFDB ]]>
TwitterFacebookLinkedIn